0000874015-18-000067.txt : 20180531
0000874015-18-000067.hdr.sgml : 20180531
20180531200244
ACCESSION NUMBER: 0000874015-18-000067
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180531
FILED AS OF DATE: 20180531
DATE AS OF CHANGE: 20180531
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MUTO FREDERICK T
CENTRAL INDEX KEY: 0001181560
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19125
FILM NUMBER: 18873145
MAIL ADDRESS:
STREET 1: 2855 GAZELLE COURT
CITY: CARLSBAD
STATE: CA
ZIP: 92010
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: IONIS PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000874015
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 330336973
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2855 GAZELLE COURT
CITY: CARLSBAD
STATE: CA
ZIP: 92010
BUSINESS PHONE: 7609319200
MAIL ADDRESS:
STREET 1: 2855 GAZELLE COURT
CITY: CARLSBAD
STATE: CA
ZIP: 92010
FORMER COMPANY:
FORMER CONFORMED NAME: ISIS PHARMACEUTICALS INC
DATE OF NAME CHANGE: 19930328
4
1
edgar.xml
PRIMARY DOCUMENT
X0306
4
2018-05-31
0000874015
IONIS PHARMACEUTICALS INC
IONS
0001181560
MUTO FREDERICK T
C/O IONIS PHARMACEUTICALS, INC.
2855 GAZELLE COURT
CARLSBAD
CA
92010
1
0
0
0
Common Stock
2018-05-31
2018-05-31
4
M
0
15000
13.88
A
22127
D
Common Stock
2018-05-31
2018-05-31
4
S
0
15000
46.45
D
7127
D
Common Stock
1500
I
By Cooley LLP Sal Def & PSP u/A DTD 2/1/74 Pension Plan
Non-Employee Director Stock Option
13.88
2018-05-31
2018-05-31
4
M
0
15000
0
D
2012-07-01
2018-06-30
Common Stock
15000
0
D
Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/26/2015.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.25 to $46.60, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
/s/Patrick R. O'Neil, attorney-in-fact
2018-05-31